Effect of combined dietary weight loss and cranberry supplementation on Non-alcoholic fatty liver disease

Effect of combined dietary weight loss and cranberry supplementation on hepatic enzymes, steatosis and inflammatory, antioxidant and apoptosis biomarkers in patients with Non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150124020765N2

Enrollment

Registered

2019-01-06

Start date

2019-01-05

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: dietary weight loss and 2 capsules containing 288 mg Cranberry extract for 12 weeks. Intervention 2: Control group: dietary weight loss and 2 placebo capsules for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: adult patients who were 18 years or older evidence of NAFLD with a steatosis grade higher or equal to 2 in ultrasonography serum alanine aminotransferase(ALT) greater than 30 IU/L formen and greater than19 IU/L for women Body mass index (BMI) Between 25 and 35

Exclusion criteria

Exclusion criteria: history of alcohol consumption or consumption of more than 10 g of alcohol per day in women and more than 20 g/d in men; Pregnancy or lactation History of other liver disorders,malignancies, cardiovascular, respiratory, and kidney disorders; Weight loss in the previous 3 months History of endocrine and metabolism disorders.

Design outcomes

Primary

Measure	Time frame
Fatty liver grade (Steatosis). Timepoint: At baseline and after 12 weeks. Method of measurement: ultrasonography.;Alanine transaminase. Timepoint: At baseline and after 12 weeks. Method of measurement: enzymatic colorimetric assay.;Aspartate aminotransferase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Alkaline phosphatase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Monocyte chemoattractant protein 1 (Mcp-1)) ?? CCL2. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Ytokeratin-18. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Total antioxidant body. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Malondialdehyde. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Tumor necrosis factor alpha. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Lipid profile. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Insulin. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa.;Fasting blood sugar. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.	—

Measure

Time frame

Fatty liver grade (Steatosis). Timepoint: At baseline and after 12 weeks. Method of measurement: ultrasonography.;Alanine transaminase. Timepoint: At baseline and after 12 weeks. Method of measurement: enzymatic colorimetric assay.;Aspartate aminotransferase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Alkaline phosphatase. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Monocyte chemoattractant protein 1 (Mcp-1)) ?? CCL2. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Ytokeratin-18. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Total antioxidant body. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Malondialdehyde. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Tumor necrosis factor alpha. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Lipid profile. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa kit.;Insulin. Timepoint: At baseline and after 12 weeks. Method of measurement: Elisa.;Fasting blood sugar. Timepoint: At baseline and after 12 weeks. Method of measurement: Enzymatic colorimetric assay.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazie Hormoznejad

Ahvaz University of Medical Sciences

r_hormozi68@yahoo.com+98 33333777

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026